R&D Offer: Innovating with data

Data from Institut Curie

The health data warehouse¹  of Institut Curie - in accordance with the requirements of the reference standard of the National Commission on Informatics and Liberty (CNIL) governing the use of health data on regulatory, technical, and security aspects - brings together different types of data:

•    Structured clinical data 
•    Medical reports 
•    Medical Imaging 
•    Digitized anatomic pathology slides 
•    Omics data.

These come from healthcare, mono- or multicente clinical research, or mono- or multicentre non-clinical research (retrospective studies).

At the same time, Institut Curie benefits from a Biological Resource Center where patients' samples are stored, with their informed consent. These samples can generate new data for a dedicated project by means of mobilizing the technological platforms of Institut Curie.

Why collaborate with Institut Curie?

Institut Curie has a remarkable heritage in terms of databases thanks to the diversity of patient care, rapid implementation of new diagnostic and therapeutic tools, continuous renewal of technical equipment, access to the latest generation technologies at Institut Curie (digitization of the pathology department, new surgical robots used in courses of care, etc.), and mastery of the latest advanced technologies in the field of omics.

Expert teams in data processing and analysis  

Institut Curie has state-of-the-art technological platforms and teams from the Research Center or the Hospital Group, which help expand on the expertise in terms of data analysis and processing: 

•    The CurieCoreTech platform - Bioinformatics (CUBIC) for data management and analysis, software development and scientific computing.
•    The CurieCoreTech - High-Throughput Sequencing (ICGEX) platform for genome analysis, transcriptome, or even "single-cell" sequencing.
•    The Laboratory of Translational Imaging in Oncology (LITO) for radiobiology and molecular imaging (development of new tracers, imaging methods, and image analysis software to identify prognostic and predictive biomarkers).
•    The Diagnostic and Theranostic Medicine Division for access to the latest analysis techniques in digital pathology, with AI tools to help diagnose breast and prostate cancers, identification of genomic abnormalities present in tumors, as well as of predictive markers of the effectiveness of therapies in the patient's constitutional or circulating DNA. 
•    Chief Data Officet to support research projects and clinical studies, identify patient cohorts, provide data mapping, and make data available in accordance with current regulations.
•    The biometrics department for statistical analyses on the treatment data, development of statistical analysis plans and scripts, etc.

In addition, the expertise of all the medical teams at Institut Curie is put to good use to analyze the data generated as part of the treatment, by means of developing unique tools (clinical bioinformatics within the genetics department, medical image analysis tools, etc.).

For which projects?

As a vector of acceleration for research and innovation, data are crucial to medical progress. Institut Curie's health data are generated continuously and are a real treasure trove in terms of development of research projects and collaborations with academic and/or industrial partners along the entire value chain:

•    Identification of new biomarkers, new therapeutic targets, or drug candidates
•    Development of artificial intelligence tools for diagnostic or prognostic purposes to assist medical personnel
•    Personalization of treatment by predicting the response to treatments using multiomic data analysis tools
•    Improving patient home monitoring using connected objects (to prevent toxicity and monitor the effectiveness of treatments)
•    R&D projects dedicated to digital twins to improve patient care by identifying patients with a similar profile
•    Optimization of clinical trials to facilitate recruitment and access to innovation.

¹ Institut Curie is the first Cancer Control Center, and one of the first healthcare institutions in France, to have an authorization for its Health Data Warehouse (HDW) meeting the requirements of the CNIL standard in terms of safety in particular. The HDW authorized by the CNIL in 2024 will take effect in 2025.

Discover all the data available at Institut Curie to conduct research projects reusing this data for retrospective and prospective studies:

Institut Curie's Clinical Trials
The data available at Institut Curie